Advertisement

Pharmaceutical Research

, Volume 22, Issue 1, pp 58–61 | Cite as

Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys

  • Donald E. Mager
  • Berend Neuteboom
  • William J. JuskoEmail author
Article

No Heading

Purpose.

To characterize the pharmacokinetic/pharmacodynamic (PK/PD) properties of a new polyethylene glycol (PEG) conjugate formulation of interferon (IFN)-β 1a following subcutaneous (SC) administration in monkeys.

Methods.

Single SC injections of 0.3, 1, and 3 million international units (MIU)/kg of PEG-IFN-β 1a were administered to 3 groups of cynomolgus monkeys (n = 4 each). Plasma concentrations of drug and neopterin, a classic biomarker for IFN-β PD, were measured at various time-points after dosing. PK/PD profiles were described by noncompartmental methods and pooled data by an integrated mathematical model, where fixed and delayed concentration-time profiles were used as driving functions in an indirect stimulatory response model.

Results.

PEG-IFN-β 1a was rapidly absorbed, with peak concentrations observed at about 4–5 h. Compared to previous identical SC doses of IFN-β 1a, administration of 1 and 3 MIU/kg of pegylated drug resulted in 27- and 16-fold increases in area under the concentration-time curves. Neopterin concentrations followed a typical dose-dependent biphasic pattern. Pooled PD profiles were well-described by the PK/PD model, and the neopterin elimination rate (0.0190 h−1) is consistent with previous estimates.

Conclusions.

The PEG-modification of IFN-β 1a provides enhanced drug exposure and similar pharmacodynamics of neopterin compared to the unmodified formulation.

Key words:

interferon-beta 1a neopterin pharmacodynamics pharmacokinetics polyethylene glycol 

Abbreviations

Ap

amount of drug in central compartment

Asc

amount of drug in SC administration site

At

amount of drug in non-specific binding compartment

k′

first-order rate constant of drug absorption to and elimination from central compartment

k12

first-order rate constant of drug distribution from central to nonspecific binding compartment

A21

first-order rate constant of drug distribution from nonspecific binding to central compartment

kin

zero-order rate constant of neopterin production

kout

first-order rate constant of neopterin elimination

N

neopterin plasma concentration

N0

baseline or time-zero neopterin concentration

SC50

drug concentration producing 50% of Smax

Smax

capacity factor for drug stimulation of kin

τ

pharmacodynamic time-lag

V/F

volume of distribution of PEG-IFN-β 1a corrected for bioavailability

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    1. Y. Sugiyama and M. Hanano. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res. 6:192–202 (1989).Google Scholar
  2. 2.
    2. J. M. Harris and R. B. Chess. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2:214–221 (2003).Google Scholar
  3. 3.
    3. R. Mehvar. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 3:125–136 (2000).Google Scholar
  4. 4.
    4. R. B. Pepinsky, D. J. LePage, A. Gill, A. Chakraborty, S. Vaidyanathan, M. Green, D. P. Baker, E. Whalley, P. S. Hochman, and P. Martin. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 297:1059–1066 (2001).Google Scholar
  5. 5.
    5. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457–478 (1993).Google Scholar
  6. 6.
    6. D. Z. D’Argenio and A. Schumitzky. ADAPT II User’s Guide, Biomedical Simulations Resource, Los Angeles, 1997.Google Scholar
  7. 7.
    7. J. Gabrielsson and D. Weiner. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm, 1997.Google Scholar
  8. 8.
    8. D. E. Mager, B. Neuteboom, C. Efthymiopoulos, A. Munafo, and W. J. Jusko. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β 1a in monkeys. J. Pharmacol. Exp. Ther. 306:262–270 (2003).Google Scholar
  9. 9.
    9. G. Levy. Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56:248–252 (1994).Google Scholar
  10. 10.
    10. K. Nieforth, R. Nadeau, I. Patel, and D. Mould. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 59:636–646 (1996).Google Scholar
  11. 11.
    11. K. A. Powers, N. M. Dixit, R. M. Ribeiro, P. Golia, A. H. Talal, and A. S. Perelson. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin. Liver Dis. 23:13–18 (2003).Google Scholar
  12. 12.
    12. D. E. Mager and W. J. Jusko. Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Ther. 70:210–216 (2001).Google Scholar
  13. 13.
    13. P. Glue, J. W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. K. Gupta, M. Salfi, and S. Jacobs. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68:556–567 (2000).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Donald E. Mager
    • 1
  • Berend Neuteboom
    • 2
  • William J. Jusko
    • 1
    Email author
  1. 1.Department of Pharmaceutical SciencesUniversity at Buffalo, State University of New YorkBuffaloUSA
  2. 2.Serono Pre-Clinical Development SiteIstituto di Ricerche Bio-mediche “Antoine Marxer”-RBM SpATorinoItaly

Personalised recommendations